Mr. Philippe Dubuc reports

THERATECHNOLOGIES ANNOUNCES CERTAIN PRELIMINARY Q3 2023 FINANCIAL HIGHLIGHTS

Theratechnologies Inc. expects to have positive adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) for its third quarter ended Aug. 31, 2023. Additionally, as at Aug. 31, 2023, Theratechnologies estimates that its cash, bonds and money market funds, stood at $22.9-million (U.S.).

"Theratechnologies' commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year," said Philippe Dubuc, senior vice-president and chief financial officer at Theratechnologies. "With second quarter headwinds firmly behind us, we are pleased to announce these positive results in advance of our upcoming earnings call and look forward to sharing our complete financial results."

The company is in the process of preparing its third quarter 2023 financial results and currently expects to release financial results and accompanying documents before the end of September. Earnings conference call details will be shared closer to this date.

About Theratechnologies Inc.

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

We seek Safe Harbor.